Listen to an audio podcast of the 6/1/22 for Ukoniq  . FDA withdrew its approval for the cancer medicine Ukoniq (active ingredient umbralisib) due to safety concerns. Ukoniq was approved to treat two specific types of lymphoma: marginal zone lymphoma (MZL) and follicular lymphoma (FL)

Listen to an audio podcast of the 6/1/22 for Ukoniq . FDA withdrew its approval for the cancer medicine Ukoniq (active ingredient umbralisib) due to safety concerns. Ukoniq was approved to treat two specific types of lymphoma: marginal zone lymphoma (MZL) and follicular lymphoma (FL)

FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns

FDA Drug Safety Podcasts, produced by FDA's Center for Drug Evaluation and Research, provide emerging safety information about drugs in conjunction with the release of Drug Safety Communications. For more information, please visit: www.fda.gov/drugsafetypodcasts

Share FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns

Sign up to save your podcasts

FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns

FDA withdrew its approval for the cancer medicine Ukoniq (umbralisib) due to safety concerns